Hear from Recursion's Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD at the PM360 SPARK conference in New York City on Mon., Feb. 24! 🔹 From 11-11:45am, she’s speaking on a panel addressing “Ethics of AI in Transparency in Advanced Analytics” with moderator Scott Reese, Global Head of Innovation at @EvolutionHealth; Sage Khanuja, AI, SME, Technology & Co-Founder, The Rx Assistant; and Armon Vincent, CEO, Custom House Inc. 🔹 From 1:45-2:15pm, she’s presenting a keynote on “AI in Drug Discovery and Development” where she’ll share how Recursion is transforming drug discovery and development with multimodal datasets, machine learning foundation models, and pharma’s most powerful supercomputer. 👉 Learn more and register here:  #PM360Spark

The full panel discussion from our “Era of TechBio” event at #JPM25 is now online! Hear from leading voices at the intersection of investment, technology, and healthcare discussing the TechBio vision -- including the latest wins, the remaining obstacles, and how tech breakthroughs like LLMs and AI agents are allowing us to scale at an unprecedented rate. 🔹 Panelists include: ◾ Dean Y. Li, MD, PhD,  Executive VP & President of Merck Research Laboratories ◾ Kimberly Powell, VP of healthcare at @nvidia ◾ @tonywkim, Managing Director at @BlackRock ◾ Alex Gorsky, former CEO of Johnson & Johnson The discussion was moderated by @natashaloder, health editor of @TheEconomist. ◽ Li said the various "vertical stacks" of drug discovery and development are all undergoing a shift with AI – molecular biology, chemistry, drug design, and clinical trials – and now there's a need to tie them together. ◽ Kim noted that he’s seen “horizontal tech platforms and breakthroughs applied to literally every industry except healthcare.” But that may be changing now with generative AI, he said, which has “superpowers which could finally crack the Rubik's Cube of this vertical industry.” In particular, he points to foundation models built not from language, but from physics, biology, and chemistry. ◽ Powell said “We are in the pre-training era of biology.” She added that @RecursionChris and Recursion have been on this journey for a long time, and “we now have the technology in the wet lab and the dry lab to start being able to represent the world of drugs and the world of biology.” ◽ Gorsky’s message to the audience was to not only think about how AI will impact drug discovery, “but how does it impact our entire system of the way we look at bringing therapeutics to market?” 👉 Watch the full conversation here:

How we are laying the groundwork for the first virtual cell. A new story from Allison Proffitt in @bioitworld looks at how Recursion is putting the necessary building blocks in place to build a virtual cell that includes “data and algorithms at three different layers,” namely, pathway, protein, and atomistic. 1️⃣ On pathway models, she writes that at the J.P. Morgan healthcare conference, co-founder and CEO @RecursionChris shared how Recursion is far out ahead. “We’ve already knocked out every gene in the genome of dozens of different cell types,” he said. “We’ve put millions of chemical perturbations on top of these cells. We have rich omics data from phenomics to transcriptomics. We have time course data increasingly with brightfield imaging. All of these datasets are giving us a very, very robust understanding of the gene networks that are at play.” 2️⃣ For the protein model layer, he shared that Recursion is dedicated to partnering and looks to AlphaFold as a leader in the field.  “We believe this layer will be commoditized, and that if you partner with the right group—which we are doing—you will have access to the state-of-the-art frontier protein folding, protein-protein interactions, protein-ligand interaction models.” 3️⃣ And he noted that our combination with Exscientia has given us a major advantage at the atomistic model layer – as the story notes, “a quantum mechanics/ molecular mechanics (QM/MD) team and dataset that will position the company for success.” Laying the groundwork for more to come, Chris said: “We can’t share everything today, but in the coming months, I think we will be able to tell the world that we are the leaders in this layer as well.” 👉 Read more:

In a new story from @davidwild77 at @INVIVOnow, Chief R&D and Chief Commercial Officer Najat Khan, PhD discusses her transition from big pharma, our integration with Exscientia, and why we’re all in on the “Era of TechBio.” 🔹 On her pharma-to-TechBio transition: “At J&J, I built all our AI efforts from the ground up as chief data science officer and led our strategy and portfolio organization. What I saw clearly there was that when you apply AI to problems that matter, you can have real impact. But what drew me to Recursion is that it's truly AI-native – we're not just adding AI to existing processes, we're reimagining how drug discovery and development is done from the ground up.” 🔹 On Recursion's integration with Exscientia: “The integration has been transformative across what I call the four P's: People, Platform, Pipeline, and Partnerships. On the people front, we've doubled our chemistry capabilities and added clinical development expertise in oncology...For partnerships, we're now working with Roche and Genentech, Sanofi, Bayer and Merck, applying both our biology and chemistry capabilities across these collaborations. And our pipeline has expanded with complementary programs – CDK7 from Exscientia, RBM39 from Recursion, and exciting new programs like our oral ENPP1 inhibitor in development with @rallybio.” 🔹 On the “Era of TechBio”: "We're at a unique moment where high-quality data, multimodal approaches, compute power, and AI are all coming together. For example, we have the fastest supercomputer in life sciences through our partnership with @nvidia, and it’s ranked 35th fastest globally. This enables us to analyze massive datasets to find new targets and biological insights." 👉 Read more:

A new story from @xiaofei_lin at @GENbio covers the recent data readout on our Phase 2 REC-994 program for cerebral cavernous malformations (CCM) & what it means to be first in disease. ▫️Lin writes, “50% of patients with cerebral lesions on the highest dose of REC-994 (400 mg) showed reduction in total lesion volume compared to 28% of patients on the placebo after 12 months of treatment… Similar trends were seen in patients with brainstem lesions, a population with high unmet need as cavernomas located in the brainstem are not amenable to surgical intervention.“ ▫️ In addition, she notes, the modified Rankin Scale “which is widely recognized and approved by the U.S. Food and Drug Administration (FDA) to assess functional outcomes in acute stroke trials, indicated positive trends in patients on the 400 mg arm.” ▫️ Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD said, “These preliminary results show promising MRI-based and functional outcome signals, and we look forward to continued discussions with the FDA, and the CCM scientific and patient communities on next steps.” ▫️ The story also notes that being first in disease holds certain challenges (the SYCAMORE trial is the first industry-sponsored clinical trial in CCM). “It’s an exciting opportunity to make an impact for patients. It also means that there’s an increased burden to not only prove out the molecule, but the path itself towards the treatment,” said co-founder and CEO @RecursionChris. ▫️ That path, as Lin writes, is the Recursion Operating System (OS) -- “a platform powered by the company’s proprietary phenomic datasets, spanning transcriptomics, proteomics, metabolomics, and more. The platform leverages Maps of Biology, which create millions of biological relationships by perturbing human cell lines to instill a disease state and testing compounds to reverse the cells to healthy function.” 👉 Read more: 💻 And if you missed today’s webinar and Q&A on the CCM Phase 2 trial readouts, you can access it here

Join us live today to learn more about our CCM program (SYCAMORE trial) phase 2 data — questions may be submitted at: #techbio #biotech #drugdiscovery #data

Today, Dr. @JanKarlBurkhar1, MD, Division Head of Cerebrovascular Surgery at @Penn, shared Phase 2 data for REC-994 in a late-breaking oral presentation at the International Stroke Conference in L.A. Dr. Burkhardt is the Principal Investigator of our SYCAMORE study, the first industry-initiated trial in Cerebral Cavernous Malformations (CCM), a neurovascular condition that impacts approximately 360,000 symptomatic individuals in the US and EU5. "The results of the SYCAMORE trial demonstrate safety of REC-994 for CCM patients and promising trends of efficacy including 50% of patients achieving a reduction in mean lesion volume after 12 months of treatment and improved functional outcome as assessed by mRS at the 400 mg dose,” he said. “My co-investigators and I are encouraged by these initial findings and we look forward to continued work with Recursion on the REC-994 program.” ▫️ As reported earlier, REC-992 met its primary endpoint of safety & tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse events. ▫️ In comparison to placebo, treatment with REC-994 400 mg showed promising signals in both MRI-based lesion volume reduction & functional outcome as measured by changes in the modified Rankin scale (mRS) score. ▫️ In patients with cavernomas located in the brainstem, a subset of patients with significant unmet need, decreases in mean absolute total lesion volume and improvements in mRS scores with REC-994 400 mg were also observed. Next steps will be guided by regulatory discussions & an ongoing long-term extension study. “These preliminary results show promising MRI-based and functional outcome signals, and we look forward to continued discussions with the FDA, and the CCM scientific and patient communities on next steps," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. 👉 Read more: 💻 Join the Webinar: On Thurs., Feb. 6 at 6:30am MT/8:30am ET/1:30pm GMT we will hold a webinar to present the Phase 2 data. The webinar will be broadcast here on X, as well as: ▫️ LinkedIn: & ▫️ YouTube: ✍ Submit your questions here:

How we’re leveraging AI to improve clinical trials – where most drugs in development fail. In a new story from @AlexWestchester in @GENbio, he talks to Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD, about Recursion’s ClinTech advances. 🔹There are 3 main focus areas: ▫️smarter trial design programs ▫️accelerating patient enrollment ▫️enhancing evidence generation “Most TechBio companies are focused in the drug discovery space,” Najat says. “But we actually have a pipeline in development, and 65 to 70% of the time and money is spent in clinical development. We want to be first in class, best in class, and best in industry—not just using AI in discovery, but also in development.” Strategies we’re employing include using real-world data to simulate clinical trials before launching them, i.e., “leveraging all of the multimodal data and causal AI to determine who are the right patients… [and] estimating things such as probability of operational success before we hit go.” We’re also, as the story notes, “using real world data and machine learning algorithms to predict hotspots of where patients are likely to be found, aiming to improve upon the low 4% of eligible patients who enter trials.” Finally, we’re using AI in trial design to pursue enhanced generation of evidence. “When you have open label studies for rare diseases,” Najat says, “you have a single arm. Can you contextualize the natural history of the patients better, and also the natural course of treatment for the patients better? This is something where we will engage regulators, etcetera, to be able to augment the package that we are generating.” 👉Read more:

✍ Submit your questions for the webinar here:

“For a TechBio company to have so many programs, it has to be powered by something that's different from how we do things today.” In a panel discussion on “Our AI Future” from @FiercePharma at the @jpmorgan Healthcare Conference, Chief R&D and Chief Commercial Officer Najat Khan, PhD described how Recursion is leveraging our multi-omic data stack to train AI models and unlock biological insights. We’re building a state-of-the-art data stack with “Genetics, transcriptomics, proteomics, phenomics, patient and real world data,” she said, not only to discover new targets, but to better understand biological pathways and connections. Once we find those connections, we use generative AI and active learning to “design molecules and optimize them to be more drug like.” 👉 Learn more about Recursion's technology: #JPM25 #TechBio

“We see TechBio as one of the major opportunity areas for AI applications.” – @zackbogue, managing partner, @DCVC ▪️ A new Deep Tech Opportunities Report from DCVC highlights the advantages of TechBio, defined as “the new branch of the AI industry that concen­trates on creating large, robust, highly structured, proprietary biological and chemical datasets to fuel advanced computation and raise the hit rate in drug discovery.” 🔹 It’s about leading with data for better predictions. ▪️ TechBio companies, they write, are “built to collect the raw data that will reveal, through in silico modeling, which hypotheses and drug candidates are most worth testing. These tests then generate even more data that can be used to make even better predictions. The end result: more leads at lower cost and lower risk.” ▪️ As one of the earliest TechBio companies, they note, Recursion has been focused on “generating vast amounts of biological and chemical data — more than 50 petabytes and counting, including phenomics data showing how toxins, pathogens, genetic changes, and candidate drug molecules affect the morphology of individual cells.” ▪️ “They have one of the biggest datasets out there, which puts them at the vanguard of the data race in biopharma,” says Bogue. 👉 Read more:

In an interview with @Forbes, co-founder and CEO @RecursionChris addresses how an AI-led approach can help improve the 90% failure rate of drugs in clinical trials. In 2013, Chris says, “We founded the company already using basic machine learning classifiers” developed during his academic work with Dean Y. Li, MD, PhD of @Merck. In just a couple years, “we were experimenting with convolutional neural networks and full-blown AI. Today, we run the fastest supercomputer of any biopharma company in the world where we train massive convolutional neural networks and other AI tools to take on this incredible challenge in biology.” But AI by itself is nothing without the high-quality data on which to train, he adds. That’s why, as he explains, we’ve been focused from our earliest days on building the biology data to train the algorithms needed to decode biology and deliver better outcomes. 👉 Watch the full interview here:

Highlights from our Era of TechBio event at #JPM25. Our event at the San Francisco Mint during the @jpmorgan Healthcare Conference was a reminder of how far we have come -- building the data, the models, and the lab automation to bring us to this inflection point – and of what we need to do to accelerate the AI-enabled future of drug discovery even further. With thought leaders from investment, pharma and academia, we set out to answer the question asked by Chief R&D and Chief Commercial Officer Najat Khan, PhD at the onset of the event, “Where is the era of TechBio today?” ▪️ “The impossible,” said Dean Y. Li, MD, PhD of @Merck Research Laboratories, “is maybe just becoming probable.” ▪️ Kimberly Powell of @nvidia noted that digital intelligence has the capacity to “advance science in incredible ways.” ▪️ @tonywkim of @BlackRock pointed to the importance of end-to-end “horizontal platforms” in this new era. ▪️ Alex Gorsky, formerly of @JNJInnovation, reminded the audience that we must always be focused on not just the technology, but “the value we are providing.” ▪️ In a fireside chat with @natashaloder of @TheEconomist, CRISPR pioneer @DoudnaJennifer talked about the incredible breakthroughs that are becoming possible as we begin to aggregate disparate data types. ▪️ Closing out the event, co-founder and CEO @RecursionChris encouraged the audience to “go after big swings,” adding: “We are an industry with so much potential for impact, but there’s so much more we can do.”

See us at SLAS! We’ve got two presentations at the @SLAS_Org Conference happening Jan. 25-29 in San Diego, focused on how we are using AI and automation to discover and design first-in-class and best-in-class molecules significantly faster than industry average. 🔹 On Mon., Jan 27, 11am-11:30am PST, Patrick Collins, Executive Director of Lab Automation, will present on “AI-Enabled Chemistry: Automating Iterative Discovery and Synthesis” – sharing how we are advancing both precision design and precision synthesis, with our generative algorithms suggesting highly diverse and complex molecules, and understanding what can and cannot be synthesized as early as possible. 🔹 On Mon., Jan 27, 11:30am-12pm PST, Nicola Richmond, VP of AI will present on “Industrializing Drug Discovery with AI and Automation” sharing Recursion’s approach to drug discovery using lab automation and AI – creating Maps of Biology that lead to unbiased discovery of novel disease targets, and improving the cost, speed and efficiency of end-to-end drug discovery and development. The talk is sponsored by Drug Discovery World. 👉 Learn more: #SLAS2025

How we’re leveraging AI to address the key pain points in drug discovery – and working to reduce 90% failure rates. Speaking to @BloombergRadio, Chief R&D and Chief Commercial Officer Najat Khan shared how Recursion is directly addressing the pain points that lead to failures in the clinic through our AI-enabled Maps of Biology. 🔹On Recursion’s AI-enabled approach. “What Recursion is doing is leveraging AI and high-quality data that is generated in our own labs at scale” to build AI algorithms that are used to “really understand what is driving the disease.” Then, “we use generative AI to design molecules that someone –even a PhD organic chemist – never considered before.” And that leads to our medicines in the clinic. 🔹On using AI to improve the speed and efficiency with which we produce first-in-class molecules. Traditionally, “It takes 42-50 months to get into the clinic.” Recursion's REC-1245 RBM39 degrader for solid tumors and lymphoma “took 18 months” with “less than 200 molecules synthesized. Usually in industry – and I come from large pharma – you’re making 3,000, 4,000, 5,000 compounds. So we’re doing things better, faster, and the insights are a first-in-class molecule, which means nobody has come up with this before.” 🔹On the importance of high-quality, proprietary data. “Even before we talk about AI, data is the differentiator. And fit-for-purpose datasets. At Recursion, we have around 60 petabytes of data…It’s having a wet lab and dry lab. Generating data, using data to train your algorithms, and those algorithms are predicting which experiments you should make.” With Maps of Biology, we’re able to understand “not just what’s driving the disease, but everything that’s connected to it. Think of it as the highways that connect across our different cells and organs.” 👉Watch the full interview here: